Comparative Pharmacology
Head-to-head clinical analysis: PAZOPANIB HYDROCHLORIDE versus RETEVMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAZOPANIB HYDROCHLORIDE versus RETEVMO.
PAZOPANIB HYDROCHLORIDE vs RETEVMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pazopanib is a multi-targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β), and stem cell factor receptor (c-Kit). It also inhibits other kinases such as fibroblast growth factor receptors (FGFR-1, -3), cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor (c-Fms).
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). Do not crush tablets.
160 mg orally twice daily
None Documented
None Documented
Terminal half-life is approximately 31 hours, supporting once-daily dosing.
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Primarily fecal (83%), with renal elimination accounting for <4% of the administered dose.
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor